Jeffrey D Bradley1, Chen Hu2,3, Ritsuko R Komaki4, Gregory A Masters5, George R Blumenschein4, Steven E Schild6, Jeffrey A Bogart7, Kenneth M Forster8, Anthony M Magliocco9, Vivek S Kavadi10, Samir Narayan11, Puneeth Iyengar12, Clifford G Robinson13, Raymond B Wynn14, Christopher D Koprowski15, Michael R Olson16, Joanne Meng17, Rebecca Paulus2, Walter J Curran18, Hak Choy12. 1. Emory University School of Medicine, Atlanta, GA. 2. NRG Oncology Statistics and Data Management Center, Pittsburgh, PA. 3. Johns Hopkins University School of Medicine, Baltimore, MD. 4. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. 5. Medical Oncology Hematology Consultants, PA, Newark, DE. 6. Mayo Clinic, Phoenix, AZ. 7. State University of New York, Syracuse, NY. 8. Geisinger Medical Center, Danville, PA. 9. Moffitt Cancer Center, Tampa, FL. 10. Texas Oncology-Sugar Land, Sugar Land, TX. 11. Saint Joseph Mercy Hospital, Ann Arbor, MI. 12. The University of Texas Southwestern Medical Center, Dallas, TX. 13. Washington University School of Medicine, St Louis, MO. 14. UPMC Shadyside Hospital, Pittsburgh, PA. 15. Christiana Care Health Community Clinical Oncology Program, Newark, DE. 16. Baptist MD Anderson Cancer Center, Jacksonville, FL. 17. Ottawa Hospital and Cancer Center, Ottawa, Ontario, Canada. 18. Emory University, Atlanta, GA.
Abstract
PURPOSE: RTOG 0617 compared standard-dose (SD; 60 Gy) versus high-dose (HD; 74 Gy) radiation with concurrent chemotherapy and determined the efficacy of cetuximab for stage III non-small-cell lung cancer (NSCLC). METHODS: The study used a 2 × 2 factorial design with radiation dose as 1 factor and cetuximab as the other, with a primary end point of overall survival (OS). RESULTS: Median follow-up was 5.1 years. There were 3 grade 5 adverse events (AEs) in the SD arm and 9 in the HD arm. Treatment-related grade ≥3 dysphagia and esophagitis occurred in 3.2% and 5.0% of patients in the SD arm v 12.1% and 17.4% in the HD arm, respectively (P = .0005 and < .0001). There was no difference in pulmonary toxicity, with grade ≥3 AEs in 20.6% and 19.3%. Median OS was 28.7 v 20.3 months (P = .0072) in the SD and HD arms, respectively, 5-year OS and progression-free survival (PFS) rates were 32.1% and 23% and 18.3% and 13% (P = .055), respectively. Factors associated with improved OS on multivariable analysis were standard radiation dose, tumor location, institution accrual volume, esophagitis/dysphagia, planning target volume and heart V5. The use of cetuximab conferred no survival benefit at the expense of increased toxicity. The prior signal of benefit in patients with higher H scores was no longer apparent. The progression rate within 1 month of treatment completion in the SD arm was 4.6%. For comparison purposes, the resultant 2-year OS and PFS rates allowing for that dropout rate were 59.6% and 30.7%, respectively, in the SD arms. CONCLUSION: A 60-Gy radiation dose with concurrent chemotherapy should remain the standard of care, with the OS rate being among the highest reported in the literature for stage III NSCLC. Cetuximab had no effect on OS. The 2-year OS rates in the control arm are similar to the PACIFIC trial.
RCT Entities:
PURPOSE: RTOG 0617 compared standard-dose (SD; 60 Gy) versus high-dose (HD; 74 Gy) radiation with concurrent chemotherapy and determined the efficacy of cetuximab for stage III non-small-cell lung cancer (NSCLC). METHODS: The study used a 2 × 2 factorial design with radiation dose as 1 factor and cetuximab as the other, with a primary end point of overall survival (OS). RESULTS: Median follow-up was 5.1 years. There were 3 grade 5 adverse events (AEs) in the SD arm and 9 in the HD arm. Treatment-related grade ≥3 dysphagia and esophagitis occurred in 3.2% and 5.0% of patients in the SD arm v 12.1% and 17.4% in the HD arm, respectively (P = .0005 and < .0001). There was no difference in pulmonary toxicity, with grade ≥3 AEs in 20.6% and 19.3%. Median OS was 28.7 v 20.3 months (P = .0072) in the SD and HD arms, respectively, 5-year OS and progression-free survival (PFS) rates were 32.1% and 23% and 18.3% and 13% (P = .055), respectively. Factors associated with improved OS on multivariable analysis were standard radiation dose, tumor location, institution accrual volume, esophagitis/dysphagia, planning target volume and heart V5. The use of cetuximab conferred no survival benefit at the expense of increased toxicity. The prior signal of benefit in patients with higher H scores was no longer apparent. The progression rate within 1 month of treatment completion in the SD arm was 4.6%. For comparison purposes, the resultant 2-year OS and PFS rates allowing for that dropout rate were 59.6% and 30.7%, respectively, in the SD arms. CONCLUSION: A 60-Gy radiation dose with concurrent chemotherapy should remain the standard of care, with the OS rate being among the highest reported in the literature for stage III NSCLC. Cetuximab had no effect on OS. The 2-year OS rates in the control arm are similar to the PACIFIC trial.
Authors: Stephen G Chun; Chen Hu; Hak Choy; Ritsuko U Komaki; Robert D Timmerman; Steven E Schild; Jeffrey A Bogart; Michael C Dobelbower; Walter Bosch; James M Galvin; Vivek S Kavadi; Samir Narayan; Puneeth Iyengar; Clifford G Robinson; Raymond B Wynn; Adam Raben; Mark E Augspurger; Robert M MacRae; Rebecca Paulus; Jeffrey D Bradley Journal: J Clin Oncol Date: 2016-10-31 Impact factor: 44.544
Authors: Jeffrey D Bradley; Rebecca Paulus; Ritsuko Komaki; Gregory Masters; George Blumenschein; Steven Schild; Jeffrey Bogart; Chen Hu; Kenneth Forster; Anthony Magliocco; Vivek Kavadi; Yolanda I Garces; Samir Narayan; Puneeth Iyengar; Cliff Robinson; Raymond B Wynn; Christopher Koprowski; Joanne Meng; Jonathan Beitler; Rakesh Gaur; Walter Curran; Hak Choy Journal: Lancet Oncol Date: 2015-01-16 Impact factor: 41.316
Authors: Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takayasu Kurata; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Corinne Faivre-Finn; Martin Reck; Johan Vansteenkiste; David R Spigel; Catherine Wadsworth; Giovanni Melillo; Maria Taboada; Phillip A Dennis; Mustafa Özgüroğlu Journal: N Engl J Med Date: 2018-09-25 Impact factor: 91.245
Authors: Bree R Eaton; Stephanie L Pugh; Jeffrey D Bradley; Greg Masters; Vivek S Kavadi; Samir Narayan; Lucien Nedzi; Cliff Robinson; Raymond B Wynn; Christopher Koprowski; Douglas W Johnson; Joanne Meng; Walter J Curran Journal: J Natl Cancer Inst Date: 2016-05-19 Impact factor: 13.506
Authors: Andy Trotti; A Dimitrios Colevas; Ann Setser; Valerie Rusch; David Jaques; Volker Budach; Corey Langer; Barbara Murphy; Richard Cumberlin; C Norman Coleman; Philip Rubin Journal: Semin Radiat Oncol Date: 2003-07 Impact factor: 5.934
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1976-12 Impact factor: 7.640
Authors: Maria Thor; Joseph O Deasy; Chen Hu; Elizabeth Gore; Voichita Bar-Ad; Clifford Robinson; Matthew Wheatley; Jung Hun Oh; Jeffrey Bogart; Yolanda I Garces; Vivek S Kavadi; Samir Narayan; Puneeth Iyengar; Jacob S Witt; James W Welsh; Cristopher D Koprowski; James M Larner; Ying Xiao; Jeffrey Bradley Journal: Clin Cancer Res Date: 2020-05-12 Impact factor: 12.531
Authors: John M Varlotto; Zhuoxin Sun; Bonnie Ky; Jenica Upshaw; Sharyn I Katz; Thomas J Fitzgerald; Heather Wakelee; Maximilian Diehn; David A Mankoff; Christine Lovely; Chandra Belani; Kurt Oettel; Gregory Masters; Suresh Ramalingam; Nathan A Pennell Journal: Oncologist Date: 2021-03-11
Authors: Mark K Farrugia; Sung Jun Ma; Mark W Hennon; Chukwumere E Nwogu; Elisabeth U Dexter; Anthony L Picone; Todd L Demmy; Jorge A Gomez-Suescun; Simon Fung-Kee-Fung; Sai S Yendamuri; Anurag K Singh Journal: Am J Clin Oncol Date: 2021-01-01 Impact factor: 2.339
Authors: Maja Guberina; Kaid Darwiche; Hubertus Hautzel; Till Ploenes; Christoph Pöttgen; Nika Guberina; Ken Herrmann; Lale Umutlu; Axel Wetter; Dirk Theegarten; Clemens Aigner; Wilfried Ernst Erich Eberhardt; Martin Schuler; Rüdiger Karpf-Wissel; Martin Stuschke Journal: Eur J Nucl Med Mol Imaging Date: 2021-02-05 Impact factor: 9.236
Authors: Olsi Gjyshi; Ting Xu; Adnan Elhammali; David Boyce-Fappiano; Stephen G Chun; Saumil Gandhi; Percy Lee; Aileen B Chen; Steven H Lin; Joe Y Chang; Anne Tsao; Carl M Gay; X Ronald Zhu; Xiaodong Zhang; John V Heymach; Frank V Fossella; Charles Lu; Quynh-Nhu Nguyen; Zhongxing Liao Journal: J Thorac Oncol Date: 2020-10-22 Impact factor: 15.609
Authors: Andrew Hope; Maikel Verduin; Thomas J Dilling; Ananya Choudhury; Rianne Fijten; Leonard Wee; Hugo Jwl Aerts; Issam El Naqa; Ross Mitchell; Marc Vooijs; Andre Dekker; Dirk de Ruysscher; Alberto Traverso Journal: Cancers (Basel) Date: 2021-05-14 Impact factor: 6.639